GS 438

Drug Profile

GS 438

Alternative Names: PMEG

Latest Information Update: 22 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Academy of Sciences of the Czech Republic; Nonindustrial source
  • Developer Gilead Sciences; Nonindustrial source
  • Class Antineoplastics; Antivirals; Nucleotides; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Herpes simplex virus infections; Human papillomavirus infections; Polyomavirus infections; Solid tumours

Most Recent Events

  • 13 Jun 2005 Preclinical trials in Solid tumours in USA (unspecified route)
  • 13 Jun 2005 Data presented at the 18th International Conference on Antiviral Research (ICAR-2005) have been added to the Cancer pharmacodynamics section
  • 25 Jul 2001 This compound is still in active development as a potential anticancer agent
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top